search
Back to results

Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients

Primary Purpose

Hepatitis C, Telemedicine

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Telemedicine
Sponsored by
University of La Laguna
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Hepatitis C

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years or older
  • have contact telephone number
  • sing the informed consent

Exclusion Criteria:

  • have advanced fibrosis (F3) or cirrhosis (F4)
  • are under surveillance by another specialist or drug addition center.

Sites / Locations

  • Hospital Universitario de CanariasRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Telemedicine-based model of care

Traditional model of care

Arm Description

Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination

Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation

Outcomes

Primary Outcome Measures

Effectiveness of the two models of care
SVR record rate

Secondary Outcome Measures

Acceptance of the intervention with a validated satisfaction questionnaire
Grade of patient satisfaction with telemedicine by a validated questionnaire

Full Information

First Posted
May 27, 2020
Last Updated
May 17, 2023
Sponsor
University of La Laguna
search

1. Study Identification

Unique Protocol Identification Number
NCT04411381
Brief Title
Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients
Official Title
Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients: a Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 25, 2020 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of La Laguna

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To achieve World Health Organization 2030 goals of hepatitis C elimination it is mandatory to document after treatment sustained virological response (SVR). Currently, patients after completing treatment do not show up for SVR assessment. The main objective of this study is to evaluate the effectiveness of a telemedicine-based model of care associated with dried blood spot testing at home to assess hepatitis C sustained virological response after treatment compared to the traditional model of care.
Detailed Description
This is a prospective, randomized study in which hepatitis C (VHC) infected patients will be randomized to two strategies for HCV care. All HCV infected patients will be evaluated in a first face-to-face consultation with the hepatologist for fibrosis evaluation and treatment prescription the same day. Patients will be invited to participate if they are: 1) 18 years or older 2) have contact telephone number 3) sing the informed consent 4) have not advanced fibrosis (F3) or cirrhosis (F4) 5) are not under surveillance by another specialist or drug addiction centre. Participants will be randomized into two strategies to assess sustained virological response (SVR) during follow-up: The traditional model of care: one appointment for venipuncture for RNA testing to assess SVR (undetectable RNA 12 weeks after treatment cessation), and an appointment with the specialist for result communication. Telemedicine-based model of care: The patient will be provided with a home kit to perform the dried blood spot (DBS) testing for HCV RNA at 12 weeks (SVR), and an appointment for teleconsultation and communicate the results. Demographic, clinical and laboratory data will be collected to evaluate the characteristics of included patients and to study predictive factors of adherence. A satisfaction questionnaire will be conducted to compare patients´ satisfaction with both health care models. The hypothesis of the study is that the adherence and SVR determination record will increase using the telemedicine-based model of care. For the present study, a 20% improvement in the adherence (SVR record) was hypothesized in the group of patients randomized to the telemedicine-based model of care compared to the traditional model of care. Taking into account power of 80%, alpha error of 5% and losses of 10% will require 68 patients per group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis C, Telemedicine

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
136 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Telemedicine-based model of care
Arm Type
Active Comparator
Arm Description
Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
Arm Title
Traditional model of care
Arm Type
No Intervention
Arm Description
Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation
Intervention Type
Other
Intervention Name(s)
Telemedicine
Intervention Description
Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
Primary Outcome Measure Information:
Title
Effectiveness of the two models of care
Description
SVR record rate
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Acceptance of the intervention with a validated satisfaction questionnaire
Description
Grade of patient satisfaction with telemedicine by a validated questionnaire
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years or older have contact telephone number sing the informed consent Exclusion Criteria: have advanced fibrosis (F3) or cirrhosis (F4) are under surveillance by another specialist or drug addition center.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Manuel Hernández-Guerra, PhD
Phone
34922678559
Email
mhernand@ull.edu.es
Facility Information:
Facility Name
Hospital Universitario de Canarias
City
La Laguna
State/Province
Santa CRUZ DE Tenerife
ZIP/Postal Code
38320
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MANUEL HERNANDEZ GUERRA, PhD
Phone
922678000

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31812456
Citation
Gomez L, Reygosa C, Morales-Arraez DE, Ramos R, Perez A, Hernandez A, Quintero E, Gutierrez F, Diaz-Flores F, Hernandez-Guerra M. Diagnostic test accuracy of the cobas 6800 system for detection of hepatitis c virus viraemia levels from dried blood spots. Enferm Infecc Microbiol Clin (Engl Ed). 2020 Jun-Jul;38(6):267-274. doi: 10.1016/j.eimc.2019.10.009. Epub 2019 Dec 4. English, Spanish.
Results Reference
background
PubMed Identifier
31811882
Citation
Averhoff F, Shadaker S, Gamkrelidze A, Kuchuloria T, Gvinjilia L, Getia V, Sergeenko D, Butsashvili M, Tsertsvadze T, Sharvadze L, Zarkua J, Skaggs B, Nasrullah M. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J Hepatol. 2020 Apr;72(4):680-687. doi: 10.1016/j.jhep.2019.11.019. Epub 2019 Dec 4.
Results Reference
background
PubMed Identifier
29946175
Citation
Cuadrado A, Llerena S, Cobo C, Pallas JR, Mateo M, Cabezas J, Fortea JI, Alvarez S, Pellon R, Crespo J, Echevarria S, Ayesa R, Setien E, Lopez-Hoyos M, Crespo-Facorro B, Aguero J, Chueca N, Garcia F, Calleja JL, Crespo J. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. Am J Gastroenterol. 2018 Nov;113(11):1639-1648. doi: 10.1038/s41395-018-0157-x. Epub 2018 Jun 27.
Results Reference
background
PubMed Identifier
31215210
Citation
Jimenez Galan G, Alia Alia C, Vegue Gonzalez M, Garcia Berriguete RM feminine, Fernandez Gonzalez F, Fernandez Rodriguez CM, Gonzalez Fernandez M, Gutierrez Garcia ML, Losa JE, Velasco M, Moreno L, Hervas R, Delgado-Iribarren A, Palacios Garcia-Cervigon G. The contribution of telemedicine to hepatitis C elimination in a correctional facility. Rev Esp Enferm Dig. 2019 Jul;111(7):550-555. doi: 10.17235/reed.2019.6152/2018.
Results Reference
background

Learn more about this trial

Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients

We'll reach out to this number within 24 hrs